

**"PEPTIDES HAVING, FOR EXAMPLE, AN ANTIANGIOGENIC
ACTIVITY AND APPLICATIONS THEREOF IN THERAPEUTICS"**

The invention relates to peptides having, in
5 particular, an antiangiogenic activity and to the
applications thereof in therapeutics.

The research carried out by the inventors concerning
therapeutically active peptides has led them to develop
10 constructs which have proved to be of great interest
with regard to their antiangiogenic properties.

The invention is therefore aimed at such peptides and
at taking advantage of their therapeutic properties for
15 developing medicaments. It is thus aimed at the
pharmaceutical compositions containing these peptides
as active ingredient. It is also aimed at the use of
these peptides for producing medicaments having an
antiangiogenic effect, for the treatment of pathologies
20 associated with hypervascularization.

The peptides according to the invention are
characterized in that they are cyclized peptides
corresponding to the sequence

- 25 SEQ ID No 1: $X_1X_2RGDX_3FGX_4X_5LLFIHFX_6IGSX_7HSX_8IX_9$ in which:
- the letters without any numerical index correspond
to amino acids defined by the single-letter
international code,
 - X_1 is either a G or a GG, the amino-terminal end
30 of which is free, alkylated, acylated, or in
particular acetylated, or contains a labeling
group, such as the biotinyl group,
 - X_2 is either a C, in which case $X_2 = X_4$, the two Cs
then being connected by a disulfide bridge, or X_2
35 is capable of forming a lactam bridge with X_4 , one
of X_2 or X_4 being an amino acid bearing an acid
group, such as A or D, the other bearing an amino
function, such as Q or N,

- X_3 is either an M motif or a norleucine motif,
- X_5 is either a motif, or a succession of two di-, tri- or tetrapeptide motifs composed of G or a combination of G and of S, such as GG, GGG, GGGG, GGS, GGGS or GSGGS, or else X_5 is a C motif, the side chain (thiol function) of which serves as a point for covalent bonding with a 3-nitro-2-pyridinesulphenyl group (Npys; Drijfhout et al., 1988 Int J Peptide protein Res, 32: 161-166) located on the N-terminal end of the next amino acid (L),
- X_6 is either an R motif or a K motif,
- X_7 is either an R motif or a K motif,
- X_8 is either an R motif or a K motif,
- X_9 is an aliphatic amino acid (such as G or A), the C-terminal end of which is amidated.

These peptides contain from 25 to 35 amino acids.

- 20 A peptide of this type corresponds to the sequence
SEQ ID No 2: GG*CRGDMFG*CGLLFIHFRIGSRHSRIG (*indicates
a disulfide bridge connecting the two C motifs).

- Other peptides are as defined above and have an
25 alkylated group at their N-terminal end.

In even other peptides, one or more amino acids are replaced with their dextrorotary form (D_{aa}).

- 30 Other peptides according to the invention correspond to
SEQ ID No 1 above, but contain one or more peptide
bonds so as to form bioisosters. Mention will, for
example, be made of the reduction of an amide bridge to
-CH₂NH-, or a retro-inverso reaction, as defined by
35 Goodman and Ro (1995, in Burger's Medicinal Chemistry,
Fifth ed vol. 1 pages 803-861, edited by ME Wolff).

As variants of the peptide of sequence SEQ ID No 2
exposing the RGD motif via a disulfide bridge between

two cysteines, mention will be made of the peptides of sequences SEQ ID No 3 to 10:

SEQ ID No 3: GG*CRGDMFG*CGLLRIHFRIGSRHSRIG
5 SEQ ID No 4: GG*CRGDMFG*CGG-LFIHFRIGSRHSRIG
SEQ ID No 5: GG*CRGDMFG*CGSLFIHFRIGSRHSRIG
SEQ ID No 6: GG*CRGDMFG*CGLLFIHFKIGSRHSRIG
SEQ ID No 7: GG*CRGDMFG*CGLLFIHF^NRIGSRHSRIG
(^NR representing an N-alkylarginine motif)
10 SEQ ID No 8: GG*CRGDMFG*CGLLSRHFRIGSRHSRIG
SEQ ID No 9: GG*CRGDMFG*CGLLSIHFRIGSRHSRIG
SEQ ID No 10: GG*CRGDMFG*CGLLFRHFRIGSRHSRIG

Other peptides of the invention contain a sequence
15 SEQ ID No 11: X-R-G-D-M-F-GX'
exposing the RGD motif via a lactam bridge between the
amino acids X (X)-C-O-NH-(X'), X and X' being amino
acids such that one bears an acid group and the other
bears an amine.

20

Preferred peptides of this group correspond to the
sequences SEQ ID No 12 to SEQ ID No 23:

SEQ ID No 12: GGXRGDMFGX'GLLFIHFRIGCRHSRIG
25 SEQ ID No 13: GGXRGDMFGX'GLLFIFRIGCRFSRIG
SEQ ID No 14: GGXRGDMFGX'GLLFIHFRIGSRHSRIG
SEQ ID No 15: GGXRGDMFGX'GLLRIHFRIGSRHSRIG
SEQ ID No 16: GGXRGDMFGX'GG-LFIHFRIGSRHSRIG
SEQ ID No 17: GGXRGDMFGX'GSLFIHFRIGSRHSRIG
30 SEQ ID No 18: GGXRGDMFGX'GLLFIHFKIGSRHSRIG
SEQ ID No 19: GGXRGDMFGX'GLLFIHF^NRIGSRHSRIG
(^NR representing an N-alkylarginine motif)
SEQ ID No 20: GGXRGDMFGX'GLLSRHFRIGSRHSRIG
SEQ ID No 21: GGXRGDMFGX'GLLSIHFRIGSRHSRIG
35 SEQ ID No 22: GGXRGDMFGX'GLLFRHFRIGSRHSRIG
SEQ ID No 23: GGXRGDMFGX'GLLFIHFRIGSRHSRIG

Said sequences can be modified, i.e. can correspond to
the native peptide but contain one or more different

acids that are chemically modified, provided that these modifications do not affect the desired function. Mention will in particular be made of the replacement of Met with nor-Leu, and Arg with N-alkyl Arg, which
5 makes it possible in particular to stabilize the construct. These modifications also comprise an acyl, in particular an acetyl, group in the N-terminal position.

10 The peptides of the invention are also characterized in that they induce apoptosis in human endothelial cells expressing $\alpha V\beta 3$ receptors.

They are also advantageously characterized in that they
15 undergo endocytosis by human endothelial cells expressing $\alpha V\beta 3$ receptors, localize in the mitochondrial compartment and exert a mitochondriotoxic effect.

20 When a peptide as developed above, or as defined above, is brought into contact with endothelial cells, specific recognition of the $\alpha V\beta 3$ integrins at the surface of the endothelial cells is observed, which allows endocytosis of the chimeric peptide. Once
25 internalized, the peptide localizes transiently in the lysosomes, as shown in confocal microscopy, and gradually becomes distributed within the mitochondrial compartment.

30 It will be noted that the specificity of the peptides of the invention results from the addition of the mitochondrial toxic part to integrin ligands so as to exert a toxicity via the mitochondrial toxicity pathway, the integrin ligands being present for the
35 purposes of targeting and themselves having no angiostatic activity.

As illustrated by the examples given hereinafter, the treatment of human primary endothelial cells with doses

of peptides of the order of one micromolar results in dissipation of the mitochondrial transmembrane potential ($\Delta\psi_m$), in the release of mitochondrial cytochrome c, in the exposure of phosphatidylserine and
5 in the condensation of nuclear chromatin.

These peptide constructs have the advantage of a lack of toxicity on $\alpha V\beta 3$ -negative cells.

10 The invention is therefore also aimed at taking advantage of these properties for selectively inducing PMM and apoptosis in angiogenic endothelial cells in the context of therapeutic strategies, in particular anticancer strategies, or the treatment of arthritis or
15 of diabetic retinopathy.

The pharmaceutical compositions according to the invention are characterized in that they contain a therapeutically effective amount of at least one
20 peptide, as defined above, in combination with a pharmaceutically acceptable vehicle.

These compositions are advantageously in the pharmaceutical forms suitable for their administration
25 by injection.

Mention will in particular be made of injectable solutions for intravenous administration.

30 The invention is also aimed at the use of peptide constructs as defined above, for producing antiangiogenic medicaments for the treatment of pathologies due to hypervascularization.

35 Mention will in particular be made of the treatment of solid tumors such as pulmonary tumors, adenomas, melanomas, prostate cancer, breast cancer, colon cancer, pancreatic cancer or osteosarcomas. The invention also applies to the treatment of diabetic

retinopathies and of arthritis.

The dosages of the administration forms and the treatments will be determined by those skilled in the art according to the pathology to be treated and to the patient's condition.

Other characteristics and advantages of the invention will be given in the examples which follow and which refer to the construct SEQ ID No 2 (hereinafter referred to as TEAM-VP)

SEQ ID No 2: GG*CRGDMFG*C-GG-LLFIHFRIGSRHSRIG-amide with or without biotin, "*" indicating a cyclization by formation of a disulfide bridge. Reference will be made to figures 1 to 3, which represent, respectively,

- figure 1, analysis of the cytotoxicity on endothelial cells,
- figure 2, recognition of the CycRGD motif by $\alpha V\beta 3$ integrins,
- figure 3, the effects of TEAM-VP on isolated mitochondria and HUVEC cells.

Examples:

Analysis of the cytotoxicity of TEAM-VP on endothelial cells

a. The HUVEC cells were incubated for 24 h with 5-30 μ m of peptide CycRGD, LLFIHFRIGSRHSRIG-amide (C4) or TEAM-VP, and then labeled with 7-AAD and analyzed by flow cytometry (figure 1a).

30

b. The HUVEC cells were incubated for 24, 48, 72 and 96 h with 15 μ m of TEAM-VP and then labeled with 7-AAD and analyzed by flow cytometry (figure 1b).

Recognition of the CycRGD motif by $\alpha V\beta 3$ integrins

a. Analysis of cell binding:

The HUVEC cells were incubated for 45 min at ambient temperature with the following peptides: GGCRGDMFGCGG-amide (linear RGD), GG*CRADMFG*CGG-amide

(CycRAD) and GG*CRGDMFG*CGG-amide (CycRGD) (0.5 to 2 μ m) labeled with FITC, and were analyzed by flow cytometry (figure 2a).

5 b. Chasing off the CycRGD peptide with said peptide:

The HUVEC cells were or were not preincubated for 30 min at ambient temperature with 200 μ M of nonlabeled CycRGD peptide before the addition of FITC-CycRGD peptide (10 μ M) for 45 min., and were analyzed by flow
10 cytometry (figure 2b).

c. Competition for the integrin sites:

The HUVEC cells were or were not preincubated for 30 min at ambient temperature with 25 μ M of peptide
15 CycRGD, CycRAD, GRGDS and GRGES before the addition of FITC-CycRGD peptide (0.5 μ M), and were then analyzed by flow cytometry (figure 2c).

20 d. Correlation between expression of integrins, binding and toxicity of the peptides:

HUVEC, HMVECD, MCF-7, MDA, HeLa, HT-29, Jurkat, CEM and PBMC cells were labeled with antibodies directed against the α V β 3 and α V β 5 integrins and were analyzed by flow cytometry. The binding of the CycRGD peptide
25 and the induction of apoptosis by TEAM-VP on the various cell types were measured (figure 2d).

+ Study of the peptide entry process:

The FITC-CycRGD and TEAM-VP (FITC) peptides enter the
30 HUVECs and colocalize with dextran beads (cotreatment for 5 h). The entry of TEAM-VP and of the dextran beads is inhibited by treatment with sodium azide + deoxyglucose, indicating entry of the peptide by endocytosis. No entry of the FITC-CycRAD peptide
35 into HUVECs, nor entry of the FITC-CycRGD peptide into HeLas is observed.

+ Intracellular routing of TEAM-VP:

HUVECs treated with TEAM-VP for 8, 24 and 32 h are

observed using a confocal microscope.

TEAM-VP visualized with Streptavidin-Texas Red
codistributes with the lysosomes (anti-Lamp2-FITC) at
5 8 h of treatment and would appear to leave these
organelles at 24 h. TEAM-VP visualized with
Streptavidin-FITC partially codistributes with the
mitochondria (anti-VDAC) at 24 h and totally
codistributes at 32 h. No codistribution with the Golgi
10 apparatus (anti-Golgin) is observed throughout the
treatment.

Effects of TEAM-VP on isolated mitochondria and HUVEC cells

15 a. Effect on isolated mitochondria:

Induction of mitochondrial swelling:

The isolated mitochondria were incubated with the
CycRGD or TEAM-VP peptide in the presence or absence of
bongkreikic acid (BA, 50 μ M), of cyclosporin A (CsA,
20 10 μ M) and of DIDS (8 μ M).

Induction of the drop in mitochondrial membrane potential:

The isolated mitochondria were incubated with 1 μ M of
25 TEAM-VP or its controls (C1, C2, C3), labeled with JC-1
and analyzed by flow cytometry (figure 3a),

SEQ ID No 24: C1 = GG*CRADMFG*CGLLFIHFRIGSRHSRIGamide

SEQ ID No 25: C1 = GG*CRGDMFG*CGLLFIHFAIGSRHSAIGamide

30 SEQ ID No 26: C3 = RKKRRQRRRGLLFIHFRIGSRHSRIGamide

b. Release of cytochrome c:

The isolated mitochondria were incubated with
alamethicin (5 μ g/ml) or TEAM-VP (10 μ M) and the
35 supernatant was analyzed by Western blotting with an
anti-cytochrome c (figure 3b).

c. Analysis of nuclear apoptosis:

The HUVEC cells treated with TEAM-VP (15-40 μ M) in the

presence or absence of caspase inhibitor for 8, 16, 24 and 48 h were labeled with Hoechst and observed under an inverted microscope. The percentages of cells exhibiting intact nuclei, of stage I or stage II, are reported (figure 3c).

d. Induction of the drop in mitochondrial membrane potential and exposure of phosphatidylserines in cellula

10 The HUVEC cells were incubated for 24 h with 15 μ M of TEAM-VP, CycRGD and C4 peptide and then labeled with JC-1 or with an anti-PARP or with annexin-V-FITC, and analyzed by flow cytometry (figure 3d).

15 + Cytochrome C release in cellula:

Release of cytochrome C observed by microscopy after 24 h of treatment with TEAM-VP (10 μ M) and double labeling of the fixed cells with an anti-cytochrome c and an anti-VDAC.

20

+ Drop in mitochondrial membrane potential in cellula:

Drop in potential observed under the microscope after JC-1-labeling of the HUVEC cells treated for 16-24 h with 15 μ M of TEAM-VP peptide.

25

Animal models:

The animal models used to determine the effectiveness of the products correspond to those conventionally used (see in particular Kisher et al., 2001 Cancer Research
30 61:7669-7674, Galaup et al., 2003 Mol Therapy 7:731-740).